The final, formatted version of the article will be published soon.
SYSTEMATIC REVIEW article
Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 |
doi: 10.3389/fendo.2024.1486861
Prevalence and risk factors for type 2 diabetes mellitus in women with gestational diabetes mellitus: A systematic review and meta-analysis
Provisionally accepted- 1 Chengdu University of Traditional Chinese Medicine, Chengdu, China
- 2 Chengdu College of Arts and Sciences, Chengdu, Sichuan, China
- 3 Department of Endocrinology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China
- 4 Department of Pharmacy, Emergency General Hospital, Beijing, China
in risk factors were presented as odds ratios (OR) and corresponding 95% confidence intervals (CI). The quality of the included studies was assessed through the Newcastle-Ottawa Scale and the Agency for Healthcare Research and Quality scale.Results: This meta-analysis encompassed 46 studies involving a total of 196,494 patients. The factors most strongly associated with the risk of developing T2DM following GDM were the use of progestin-only contraceptives (odds ratio [OR]: 2.12, 95% confidence interval [CI] = 1.00-4.45, P = 0.049), recurrence of GDM (OR: 2.63, 95% CI = 1.88-3.69, P < 0.001), insulin use during pregnancy (OR: 4.35, 95% CI = 3.17-5.96, P < 0.001), pre-pregnancy body mass index (BMI) (OR: 2.97, 95% CI = 2.16-4.07, P < 0.001), BMI after delivery (OR: 4.17, 95% CI = 2.58-6.74, P < 0.001), macrosomia (OR: 3.30, 95% CI = 1.45-7.49, P = 0.04), hypertension (OR: 5.19, 95% CI = 1.31-20.51, P = 0.019), and HbA1c levels (OR: 3.32, 95% CI = 1.81-6.11, P < 0.001). Additionally, age (OR: 1.71, 95% CI = 1.23-2.38, P = 0.001), family history of diabetes (OR: 1.47, 95% CI = 1.27-1.70, P < 0.001), BMI during pregnancy (OR:1.06, 95% CI = 1.00-1.12, P = 0.056), fasting blood glucose (FBG) (OR: 1.58, 95% CI = 1.36-1.84, P < 0.001), 1-hour oral glucose tolerance test (OGTT) (OR: 1.38, 95% CI = 1.02-1.87, P = 0.037), and 2-hour OGTT (OR: 1.54, 95% CI = 1.28-1.58, P < 0.001) were identified as moderate-risk factors for the development of T2DM.The systematic review and meta-analysis identified several moderate-to high-risk factors associated with the progression of T2DM in individuals with a history of GDM. These risk factors include the use of progestin-only contraceptives, pre-pregnancy BMI, BMI after delivery, macrosomia, hypertension, persistently elevated levels of HbA1c, fasting blood glucose (FBG), 1-hour and 2-hour oral glucose tolerance tests (OGTT), age, and family history of diabetes. Our findings serve as evidence for the early prevention and clinical intervention of the progression from GDM to T2DM and offer valuable insights to guide healthcare professionals in formulating customized management and treatment strategies for female patients with diverse forms of GDM.
Keywords: diabetes, Epidemiology, Endocrinology, Prenatal Care, High-risk pregnancy, gestational diabetes mellitus, Women's Health
Received: 27 Aug 2024; Accepted: 02 Dec 2024.
Copyright: © 2024 Chen, Tang, Wang, Li, Zhang, Cui, Chen, Jin and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lichao Tang, Chengdu University of Traditional Chinese Medicine, Chengdu, China
Xinwei Wang, Chengdu University of Traditional Chinese Medicine, Chengdu, China
Xijian Zhang, Department of Endocrinology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China
Shikui Cui, Department of Endocrinology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China
Wei Chen, Department of Pharmacy, Emergency General Hospital, Beijing, China
Zhao Jin, Chengdu University of Traditional Chinese Medicine, Chengdu, China
Danping Zhu, Department of Endocrinology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.